Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.53
NAS:AMAG's Cash-to-Debt is ranked lower than
87% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NAS:AMAG: 0.53 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:AMAG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: No Debt Max: No Debt
Current: 0.53
Equity-to-Asset 0.38
NAS:AMAG's Equity-to-Asset is ranked lower than
80% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:AMAG: 0.38 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:AMAG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.85 Max: 0.98
Current: 0.38
0.33
0.98
Interest Coverage 1.08
NAS:AMAG's Interest Coverage is ranked lower than
98% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:AMAG: 1.08 )
Ranked among companies with meaningful Interest Coverage only.
NAS:AMAG' s Interest Coverage Range Over the Past 10 Years
Min: 1.08  Med: No Debt Max: No Debt
Current: 1.08
Piotroski F-Score: 4
Altman Z-Score: 0.65
Beneish M-Score: -2.94
WACC vs ROIC
3.97%
5.09%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 14.82
NAS:AMAG's Operating Margin % is ranked higher than
83% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NAS:AMAG: 14.82 )
Ranked among companies with meaningful Operating Margin % only.
NAS:AMAG' s Operating Margin % Range Over the Past 10 Years
Min: -4107.64  Med: -72.84 Max: 26.59
Current: 14.82
-4107.64
26.59
Net Margin % -0.47
NAS:AMAG's Net Margin % is ranked higher than
70% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NAS:AMAG: -0.47 )
Ranked among companies with meaningful Net Margin % only.
NAS:AMAG' s Net Margin % Range Over the Past 10 Years
Min: -3696.96  Med: -71.06 Max: 109.19
Current: -0.47
-3696.96
109.19
ROE % -0.27
NAS:AMAG's ROE % is ranked higher than
75% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NAS:AMAG: -0.27 )
Ranked among companies with meaningful ROE % only.
NAS:AMAG' s ROE % Range Over the Past 10 Years
Min: -52.39  Med: -15.27 Max: 42.96
Current: -0.27
-52.39
42.96
ROA % -0.10
NAS:AMAG's ROA % is ranked higher than
77% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NAS:AMAG: -0.10 )
Ranked among companies with meaningful ROA % only.
NAS:AMAG' s ROA % Range Over the Past 10 Years
Min: -44.82  Med: -13.1 Max: 16.42
Current: -0.1
-44.82
16.42
ROC (Joel Greenblatt) % 288.57
NAS:AMAG's ROC (Joel Greenblatt) % is ranked higher than
97% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NAS:AMAG: 288.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:AMAG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1009.91  Med: -510.9 Max: 475.79
Current: 288.57
-1009.91
475.79
3-Year Revenue Growth Rate 60.80
NAS:AMAG's 3-Year Revenue Growth Rate is ranked higher than
89% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. NAS:AMAG: 60.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:AMAG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -78.7  Med: 10.3 Max: 278.5
Current: 60.8
-78.7
278.5
3-Year EPS without NRI Growth Rate -45.80
NAS:AMAG's 3-Year EPS without NRI Growth Rate is ranked lower than
89% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NAS:AMAG: -45.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:AMAG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -51.7  Med: -8.15 Max: 100
Current: -45.8
-51.7
100
GuruFocus has detected 3 Warning Signs with AMAG Pharmaceuticals Inc $NAS:AMAG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AMAG's 10-Y Financials

Financials (Next Earnings Date: 2017-05-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AMAG Guru Trades in Q1 2016

Paul Tudor Jones 286,200 sh (New)
Jim Simons Sold Out
Scott Black Sold Out
Joel Greenblatt 204,184 sh (-5.67%)
» More
Q2 2016

AMAG Guru Trades in Q2 2016

Steven Cohen 446,300 sh (New)
Joel Greenblatt 411,912 sh (+101.74%)
Paul Tudor Jones 375,500 sh (+31.20%)
» More
Q3 2016

AMAG Guru Trades in Q3 2016

Joel Greenblatt 507,809 sh (+23.28%)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
Q4 2016

AMAG Guru Trades in Q4 2016

Paul Tudor Jones 11,200 sh (New)
Jim Simons 513,500 sh (New)
Joel Greenblatt 600,584 sh (+18.27%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:AMAG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:JNCE, NAS:ACRS, NAS:AKAO, OTCPK:PHMMF, OTCPK:CMVLF, NAS:ESPR, OTCPK:SXMDF, NYSE:MYOV, NAS:INSY, NAS:ACOR, NAS:EPZM, NAS:MGNX, NAS:AMRN, NAS:NDRM, NAS:OMER, NAS:EDIT, NAS:VSAR, NAS:CRSP, OTCPK:BPMUF, NAS:AMRI » details
Traded in other countries:AMU.Germany,
Headquarter Location:USA
AMAG Pharmaceuticals Inc is a specialty pharmaceutical company with a focus on maternal health, anemia and cancer supportive care. The Company markets Makena; Feraheme, Injection for Intravenous (IV) use; and MuGard, Mucoadhesive Oral Wound Rinse.

Founded in 1981, AMAG Pharmaceuticals uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging.

Top Ranked Articles about AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals to Present at the Deutsche Bank Health Care Conference
AMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance
AMAG Pharmaceuticals to Host First Quarter 2017 Financial Results Conference Call and Webcast on Tuesday, May 2, 2017 at 8:00 a.m. ET
AMAG Submits Supplemental New Drug Application to FDA for Makena® (Hydroxyprogesterone Caproate Injection) Auto-Injector for Subcutaneous Use
AMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement With Endoceutics for U.S. Rights to Intrarosa™ (Prasterone)
AMAG Pharmaceuticals to Present at the Needham Healthcare Conference

WALTHAM, Mass., March 28, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017 at 4:20 p.m. ET.
A live audio webcast will be accessible through the Investors section of the company’s website at www.amagpharma.com, and will be archived for 30 days.  About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com. AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. and CBR® is a registered trademark of CBR Systems, Inc.
AMAG Pharmaceuticals Contact:
Christi Waarich
Associate Director, Investor Relations
617-498-7638

Read more...
AMAG Announces Management Changes and New Commercial Appointments

WALTHAM, Mass., March 06, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced changes to the company’s executive and commercial leadership teams, including that Frank Thomas, president and chief operating officer, intends to transition out of the organization on April 30, 2017. Following this transition, Ted Myles, chief financial officer, and Joseph Vittiglio, general counsel, along with AMAG’s business development function, will report directly to William Heiden, chief executive officer of AMAG. Mr. Vittiglio joined AMAG as chief counsel in August 2015, and Mr. Myles joined the company as chief financial officer in April 2016.
“I would like to thank Frank for all of his contributions to AMAG where he has been an effective leader for the past six years, helping to build and implement our successful growth and portfolio expansion strategy,” said William Heiden. “I am especially grateful for the strong team he has helped put in place to execute on AMAG’s next stage of growth.” “It has been my honor to help lead AMAG through an exciting period of growth and change. I am very proud of everything we accomplished – from both a business and patient perspective, and I am thankful for the opportunity to work alongside Bill and such a passionate group of employees over the years,” said Mr. Thomas. “Implementation of the company’s strategic plan is on track, the management team is strong, and it’s the right time for me to step aside, spend some time with my family and pursue the next chapter in my career.” AMAG also announced key commercial leadership moves to drive future growth in maternal and women’s health, following the company’s recently announced licensing transactions for IntrarosaTM (prasterone) and bremelanotide. Paul Williams, who currently leads the company’s maternal health organization, has been appointed to lead AMAG’s newly created women’s health business. Mr. Williams, who joined AMAG in 2014, will be responsible for the launch and commercialization of Intrarosa, as well as the potential launch of bremalanotide in early 2019. Mary Trout, who joined AMAG in 2015 as part of the CBR acquisition and successfully led the integrated maternal health field sales force to achieve record sales for Makena over the past two years, has been promoted to senior vice president of sales and marketing, maternal health. In her new role, Ms. Trout will lead AMAG’s maternal health commercial functions. 

Both Mr. Williams and Ms. Trout will report to Nik Grund, AMAG’s chief commercial officer. About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of women's health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com. Forward-Looking Statements This press release contains forward-looking information about AMAG Pharmaceuticals, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, beliefs regarding the ability of AMAG’s current team to execute its next stage of growth, beliefs that the implementation of AMAG’s strategic plan is on track and expectations that the commercial leadership changes will drive future growth in maternal and women’s health are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, risks identified in AMAG’s Securities and Exchange Commission (“SEC”) filings, including its Annual Report on Form 10-K for the year ended December 31, 2016, and subsequent filings with the SEC.  AMAG cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.  AMAG disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. Makena® is a registered trademark of AMAG Pharmaceuticals IP, Ltd.  Cord Blood Registry® is a registered trademark of CBR Systems, Inc. RekyndaTM is a trademark of Palatin Technologies, Inc. IntrarosaTM is a trademark of Endoceutics, Inc.
CONTACTS:
Investors:
Linda Lennox
Vice President, Investor Relations
908-627-3424

Media:
Katie Payne
Vice President, External Affairs
202-669-6786

Read more...
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences:
Cowen and Company Annual Health Care Conference 
Monday, March 6, 2017 at 2:40 p.m. ET  
Location: Boston, MA

Raymond James Annual Institutional Investors Conference 
Wednesday, March 8, 2017 at 10:25 a.m. ET
Location: Orlando, FL

Barclays Global Healthcare Conference 
Tuesday, March 14, 2017 at 2:35 p.m. ET
Location: Miami, FL To access the live webcasts, please visit the Investors section of the company’s website at www.amagpharma.com. A replay of each event will be archived on the site for 30 days. About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of women's health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals Contact:
Christi Waarich
Associate Director, Investor Relations
617-498-7638

Read more...
Steven Cohen Buys AMAG Pharmaceuticals Company focuses on development of regenerative medicine
On July 25, Steven Cohen (Trades, Portfolio) of Point72 Asset Management gained a new holding with AMAG Pharmaceuticals Inc. (NASDAQ:AMAG). Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 4.00
AMAG's Forward PE Ratio is ranked higher than
98% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. AMAG: 4.00 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 5.27
AMAG's Price-to-Owner-Earnings is ranked higher than
91% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. AMAG: 5.27 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AMAG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.58  Med: 10.69 Max: 23.22
Current: 5.27
4.58
23.22
PB Ratio 0.91
AMAG's PB Ratio is ranked higher than
94% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. AMAG: 0.91 )
Ranked among companies with meaningful PB Ratio only.
AMAG' s PB Ratio Range Over the Past 10 Years
Min: 0.68  Med: 2.45 Max: 18.97
Current: 0.91
0.68
18.97
PS Ratio 1.69
AMAG's PS Ratio is ranked higher than
91% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. AMAG: 1.69 )
Ranked among companies with meaningful PS Ratio only.
AMAG' s PS Ratio Range Over the Past 10 Years
Min: 1.5  Med: 6.61 Max: 505.93
Current: 1.69
1.5
505.93
Price-to-Free-Cash-Flow 3.70
AMAG's Price-to-Free-Cash-Flow is ranked higher than
95% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. AMAG: 3.70 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AMAG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.32  Med: 19.93 Max: 1335.26
Current: 3.7
3.32
1335.26
Price-to-Operating-Cash-Flow 3.62
AMAG's Price-to-Operating-Cash-Flow is ranked higher than
94% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. AMAG: 3.62 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AMAG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.25  Med: 19.85 Max: 1268.5
Current: 3.62
3.25
1268.5
EV-to-EBIT 16.49
AMAG's EV-to-EBIT is ranked higher than
57% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. AMAG: 16.49 )
Ranked among companies with meaningful EV-to-EBIT only.
AMAG' s EV-to-EBIT Range Over the Past 10 Years
Min: -602.3  Med: -5.7 Max: 87.5
Current: 16.49
-602.3
87.5
EV-to-EBITDA 7.41
AMAG's EV-to-EBITDA is ranked higher than
79% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. AMAG: 7.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMAG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -148.3  Med: -5.6 Max: 367.1
Current: 7.41
-148.3
367.1
Current Ratio 2.30
AMAG's Current Ratio is ranked lower than
69% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. AMAG: 2.30 )
Ranked among companies with meaningful Current Ratio only.
AMAG' s Current Ratio Range Over the Past 10 Years
Min: 1.65  Med: 8.72 Max: 42
Current: 2.3
1.65
42
Quick Ratio 2.18
AMAG's Quick Ratio is ranked lower than
68% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. AMAG: 2.18 )
Ranked among companies with meaningful Quick Ratio only.
AMAG' s Quick Ratio Range Over the Past 10 Years
Min: 1.4  Med: 8.3 Max: 41.1
Current: 2.18
1.4
41.1
Days Inventory 123.42
AMAG's Days Inventory is ranked higher than
52% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. AMAG: 123.42 )
Ranked among companies with meaningful Days Inventory only.
AMAG' s Days Inventory Range Over the Past 10 Years
Min: 121.63  Med: 441.37 Max: 1713.48
Current: 123.42
121.63
1713.48
Days Sales Outstanding 63.37
AMAG's Days Sales Outstanding is ranked lower than
52% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. AMAG: 63.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMAG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.4  Med: 49.36 Max: 581.14
Current: 63.37
27.4
581.14
Days Payable 11.50
AMAG's Days Payable is ranked lower than
85% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. AMAG: 11.50 )
Ranked among companies with meaningful Days Payable only.
AMAG' s Days Payable Range Over the Past 10 Years
Min: 11.5  Med: 130.3 Max: 2881.25
Current: 11.5
11.5
2881.25

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.30
AMAG's 3-Year Average Share Buyback Ratio is ranked lower than
64% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. AMAG: -16.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMAG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -28.7  Med: -6.3 Max: 3.5
Current: -16.3
-28.7
3.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.59
AMAG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
94% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. AMAG: 0.59 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AMAG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.55  Med: 5.15 Max: 14.72
Current: 0.59
0.55
14.72
Price-to-Median-PS-Value 0.25
AMAG's Price-to-Median-PS-Value is ranked higher than
91% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. AMAG: 0.25 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMAG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 1.47 Max: 277.17
Current: 0.25
0.23
277.17
Earnings Yield (Greenblatt) % 6.05
AMAG's Earnings Yield (Greenblatt) % is ranked higher than
86% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. AMAG: 6.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMAG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.1  Med: 4.8 Max: 6.8
Current: 6.05
1.1
6.8

More Statistics

Revenue (TTM) (Mil) $532.1
EPS (TTM) $ -0.11
Beta0.79
Short Percentage of Float29.90%
52-Week Range $17.92 - 36.83
Shares Outstanding (Mil)34.94

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 646 565 581
EPS ($) 6.12 3.52 3.06
EPS without NRI ($) 6.12 3.52 3.06
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:AMAG

Headlines

Articles On GuruFocus.com
AMAG Pharmaceuticals to Present at the Deutsche Bank Health Care Conference Apr 26 2017 
AMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance Apr 25 2017 
AMAG Pharmaceuticals to Host First Quarter 2017 Financial Results Conference Call and Webcast on Tue Apr 19 2017 
AMAG Submits Supplemental New Drug Application to FDA for Makena® (Hydroxyprogesterone Caproate I Apr 17 2017 
AMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement With Endoceutics for U.S. Ri Apr 04 2017 
AMAG Pharmaceuticals to Present at the Needham Healthcare Conference Mar 28 2017 
AMAG Announces Management Changes and New Commercial Appointments Mar 06 2017 
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences Mar 01 2017 
Steven Cohen Increases Position in Dynavax Oct 07 2016 
Steven Cohen Buys AMAG Pharmaceuticals Jul 29 2016 

More From Other Websites
AMAG Pharmaceuticals to Present at the Deutsche Bank Health Care Conference Apr 26 2017
AMAG Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AMAG-US : April... Apr 25 2017
AMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance Apr 25 2017
AMAG Pharmaceuticals to Host First Quarter 2017 Financial Results Conference Call and Webcast on... Apr 19 2017
AMAG Files for FDA Approval of Subcutaneous Form of Makena Apr 18 2017
AMAG Submits Supplemental New Drug Application to FDA for Makena® (Hydroxyprogesterone Caproate... Apr 17 2017
AMAG Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AMAG) : April 12, 2017 Apr 12 2017
15 companies with outsized sales growth and widening profit margins Apr 07 2017
AMAG Pharmaceuticals stock surges 4% after closing $50 mln licensing agreement for menopause drug Apr 04 2017
AMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement With Endoceutics for U.S.... Apr 04 2017
Zacks.com featured highlights: PTC, Covanta Holding, Etsy, Incyte and AMAG Pharmaceuticals Mar 31 2017
5 Toxic Stocks to Get Rid Of or Play Short to Make Gains Mar 30 2017
AMAG Pharmaceuticals to Present at the Needham Healthcare Conference Mar 28 2017
Billionaires' Worst Healthcare Stock Picks for 2017 (So Far) Mar 22 2017
AMAG Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMAG-US : March... Mar 21 2017
Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for... Mar 20 2017
Two Biotech Catalysts To Watch Right Now: Bioline RX Ltd (BLRX) And AMAG Pharmaceuticals, Inc.... Mar 14 2017
AMAG Announces Management Changes and New Commercial Appointments Mar 06 2017
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences Mar 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)